Antibiotics trial supports guidelines in bronchiectasis

Azithromycin is an attractive alternative to amoxicillin-clavulanate for the management of non-severe acute exacerbations of bronchiectasis in children but should be reserved as a second-line therapy in accordance with Australian and New Zealand guidelines. Dr Vikas Goyal, from the Department of Respiratory and Sleep Medicine at the Queensland Children’s Hospital, told the 2019 ERS Congress ...

Already a member?

Login to keep reading.

© 2021 the limbic